Calendario›TVRD›TTI-101
TTI-101
Ensayo de Tvardi Therapeutics, Inc. en Carcinoma hepatocelular.
Más ensayos de: Carcinoma hepatocelular.
Todo sobre el fármaco: TTI-101.
- Fase
- Fase 1/2
- Estado
- Reclutando pacientes
- Participantes
- 193
- Centros
- 21
- Fin del objetivo primario
- may 2027
Título oficial en el registro (en inglés): A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en mar 2023.
De principio a fin
Desde que lo vigilamos, su lectura se ha retrasado 3 meses en total.
- Empieza el ensayo (mar 2023)
- Mueve la lectura: feb 2027 → may 2027 (+3 meses) · visto el 23 oct 2026
- Hoy
- Lectura de resultados may 2027 (prevista)
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Lo que ha cambiado
Movimientos registrados desde que PivotalWire vigila este ensayo. Un retraso no se anuncia: se ve comparando, y esto es la comparación ya hecha.
| Visto | Qué se mueve | Cambio |
|---|---|---|
| 23 oct 2026 | Lectura de resultados | feb 2027 → may 2027 |
Qué mide
Incidence of Adverse Events (AE) (del registro, en inglés) (hasta unos 20 meses)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 as a single agent in participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohort A Phase 2 are to assess response, progression, survival, and pharmacokinetics. The primary objectives of Cohorts B and C Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, or unresectable HCC and to determine the MTD and/or RP2D of TTI-101 when used in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C). The primary objectives of Cohorts B and C Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohorts B and C Phase 2 are to assess response, progression, survival, and pharmacokinetics.
Sigue a TVRD y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.
Más ensayos de TVRD
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| TTI-101 | Fase 2 | Completado | ago 2025 (real) |
| TTI-101 | Fase 1 | Completado | jun 2024 (real) |
| TTI-101 | Fase 1 | Interrumpido | may 2024 (real) |
Todos los de TVRD, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05440708), actualizada en oct 2026.